|Articles|May 1, 1999

May 1999
Volume 5
Issue 5

Course and Cost of Treatment for Depression with Fluoxetine, Paroxetine, and Sertraline

Author(s)James M. Russell, MD, Ernst R. Berndt, PhD, Robert Miceli, PhD

Download PDF: Course and Cost of Treatment for Depression with Fluoxetine, Paroxetine, and Sertraline

Articles in this issue

about 27 years ago

Article

Relationship between Primary Payer and Use of Proactive Immunization Practices: A National Survey

about 27 years ago

Article

Polypharmacy Management in Medicare Managed Care: Changes in Prescribing by Primary Care Physicians Resulting from a Program Promoting Medication Reviews

about 27 years ago

Article

Project LEAP of New Jersey: Lower Extremity Amputation Prevention in Persons with Type 2 Diabetes

about 27 years ago

Article

Quality of Care for Chronic Illness in Primary Care: Opportunities for Improvement in Process and Outcome Measures

about 27 years ago

Article

Assessment of Patient Satisfaction with a Formulary Switch from Omeprazole to Lansoprazole in Gastroesophageal Reflux Disease Maintenance Therapy

about 27 years ago

Article

Overview of Platelet Glycoprotein IIb/IIIa Receptor Antagonist Treatment in the Management of Coronary Interventions and Acute Ischemic Coronary Syndromes

about 27 years ago

Article

Benign Prostatic Hyperplasia: An Overview for Pharmacists

about 27 years ago

Article

Correspondence regarding, "How Should Managed Care Treat Onychomycosis?"

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Course and Cost of Treatment for Depression with Fluoxetine, Paroxetine, and Sertraline

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care

Cardiology Prices Vary Widely by Insurer and State

Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection

Rethinking Cardiometabolic Risk: Deepak Bhatt, MD, MPH, MBA